Results 51 to 60 of about 40,707 (134)

Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma

Clinical, Cosmetic and Investigational Dermatology, 2013
Giulio Tosti, Emilia Cocorocchio, Elisabetta PennacchioliDivisione Melanomi e Sarcomi, Istituto Europeo di Oncologia, Milano, ItalyAbstract: Approaches aimed at enhancement of the tumor specific response have provided proof for the rationale of ...
Tosti G, Cocorocchio E, Pennacchioli E
doaj  

Emerging options for the treatment of melanoma – focus on ipilimumab

ImmunoTargets and Therapy, 2014
Claire Roddie, Karl S Peggs UCL Cancer Institute, Department of Hematology, London, UK Abstract: Ipilimumab is a fully human immunoglobulin subclass G1 anticytotoxic-T-lymphocyte-antigen-4 monoclonal antibody.
Roddie C, Peggs KS
doaj  

Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database. [PDF]

Front Oncol
Yang Y, Wang F, Tong W, Lu X, Zhao F, Fang S, Wang S.   +6 more
europepmc   +1 more source

Predicting immune-related thyroiditis using polygenic risk scores in patients with advanced melanoma. [PDF]

J Immunother Cancer
Tarhini AA, Khaksar MA, Chen Z, Lee SJ, Stephen Hodi F, Li T, Yoder SJ, Streicher H, Sondak VK, Kirkwood JM, Wang X, Kanetsky PA.   +11 more
europepmc   +1 more source

Early Progressive Disease During Nivolumab Plus Ipilimumab Therapy Predicts Poor Survival in Japanese Patients with Advanced Renal Cell Carcinoma: A Single-Center 12-Week Landmark Study. [PDF]

Res Rep Urol
Furubayashi N, Tsujita J, Takayama A, Shiraishi Y, Nakamura M, Negishi T.   +5 more
europepmc   +1 more source

Pathological Complete Response to Nivolumab Plus Ipilimumab Combination Therapy in Advanced Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus. [PDF]

IJU Case Rep
Tsuchiya T, Kimura G, Takeda H, Akatsuka J, Hasegawa H, Toyama Y, Sakatani T, Shimizu A, Ohashi R, Kondo Y.   +9 more
europepmc   +1 more source

Significant Response to Nivolumab Plus Ipilimumab in Metastatic Mucinous Tubular and Spindle Cell Carcinoma: A Case Report. [PDF]

IJU Case Rep
Shimasaki S, Yamamoto S, Iguchi M, Yamashita E, Atagi K, Shiba Y, Fukata S, Satake H, Karashima T, Inoue K.   +9 more
europepmc   +1 more source

Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma. [PDF]

Front Endocrinol (Lausanne)
Hasan M, Samlowski W, Nakhle S.
europepmc   +1 more source

Incidence and impact of pseudoprogression and mixed responses in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab: a retrospective analysis. [PDF]

Acta Oncol
Caeyman A, Mammone G, Kinget L, Baldewijns M, De Wever L, Albersen M, Debruyne PR, Demeulenaere O, McTaggart ES, Saraswat S, Berghen C, De Meerleer G, Naulaerts S, Garg AD, Beuselinck B.   +14 more
europepmc   +1 more source

Dual Immune Checkpoint Blockade in Synchronous Hepatocellular and Renal Cell Carcinoma: A Real-World Case Report of Durable Dual Response. [PDF]

Oncol Res
Federico P, Canciello MA, Granata B, Bosso D, Daniele B.   +4 more
europepmc   +1 more source